Structure-based design of targeted covalent inhibitors
The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Covalent inhibition is a rapidly growing discipline within drug discovery.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Compared with noncovalent inhibitors, covalent PPI inhibitors can have the advantages of sustained inhibition and longer residence times, as covalently bound PPI targets are persistently inhibited until protein degradation and regeneration [40].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [40]
In the citing paper
“Covalent ligand screening is another ligand discovery approach that is becoming more common, whereby various methods are used to discover covalent ligands from libraries of electrophilic compounds7,12,13.”
From Advances in covalent drug discovery (2022) · cites this paper as [7]
In the citing paper
“include the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib (AbbVie) and the epidermal growth factor receptor (EGFR) inhibitor osimertinib (AstraZeneca), with sales totalling US$8.43 billion and $4.33 billion in 2020, respectively7,8.”
From Advances in covalent drug discovery (2022) · cites this paper as [7]
Citations
Cites
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Epidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170
Targeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2559 · Cited by 2,576
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Cross, D. A. E., Ashton, S. E., Ghiorghiu, S., Eberlein, C., Nebhan, C. A., Spitzler, P. J., Orme, J. P., Finlay, M. R. V., Ward, R. A., Mellor, M. J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0337 · Cited by 2,246
Self-citationComputational Methods in Drug Discovery
Sliwoski, G., Kothiwale, S., Meiler, J., & Lowe, E. W. (2014) · Pharmacological Reviews · doi:10.1124/pr.112.007336 · Cited by 2,160
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118
The resurgence of covalent drugs
Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3410 · Cited by 1,873
How were new medicines discovered?
Swinney, D. C., & Anthony, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3480 · Cited by 1,812
Thress, K. S., Paweletz, C. P., Felip, E., Cho, B. C., Stetson, D., Dougherty, B., Lai, Z., Markovets, A., Vivancos, A., Kuang, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3854 · Cited by 1,589
Research works printed but not linked: 1
- Martin-Gago, 2017, Cell Chem. Biol., 24, e585
Cited by
Items 301–371 of 371
Norman, B. H. (2021) · Burger's Medicinal Chemistry and Drug Discovery · doi:10.1002/0471266949.bmc128.pub2 · Cited by 1
Targeted Covalent Inhibition: A Prospective Way to Develop Novel HSP90 C-terminal Inhibitor
Liu, Y., & Li, Y. (2022) · Current Drug Targets · doi:10.2174/1389450123666220920111841 · Cited by 1
Erdogan, F., Chowdhury, R., Beldar, S., Chandy, T. B., Allan, R. G., de Araujo, E. D., & Gunning, P. T. (2023) · ChemRxiv · doi:10.26434/chemrxiv-2023-hfntq
Microfluidic Technologies and Platforms for Protein Crystallography
Maeki, M., & Tokeshi, M. (2019) · Bioanalysis · doi:10.1007/978-981-13-6229-3_2
Design, Synthesis and Evaluation of Covalent Inhibitors for Tissue Transglutaminase and Factor XIIIa
Akbar, A. (2019) · uO Research (University of Ottawa) · doi:10.20381/ruor-23888
Modeling Covalent Protein-Ligand Interactions
Ward, R. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11519-3
Self-citationGreinke, L. (2021) · DigitalCommons - Kennesaw State University (Kennesaw State University)
Stabilized Peptide Covalent Inhibitors
Li, Z., Zhao, H., & Wan, C. (2021) · Wiley eBooks · doi:10.1002/9783527343430.ch5
Approaching novel antibiotic targets using peptidomimetics
Paulussen, F. M. (2023) · doi:10.5463/thesis.473
Structure-based Design for Medicinal Chemists
Blaney, J., & Davis, A. M. (2023) · Royal Society of Chemistry eBooks · doi:10.1039/9781788018982-00137 · Cited by 1
Aljoundi, A. (2021) · ResearchSpace (University of KwaZulu-Natal) · doi:10.29086/10413/22663
Targeted anticancer pre-vinylsulfone covalent inhibitors of carbonic anhydrase IXPreprint
Vaškevičius, A., Baronas, D., Leitāns, J., Kvietkauskaitė, A., Rukšėnaitė, A., Manakova, E., Toleikis, Z., Kaupinis, A., Kazāks, A., Gedgaudas, M., et al. (2024) · eLife · doi:10.7554/elife.101401.1
Microfluidic Technologies and Platforms for Protein Crystallography
Maeki, M., & Tokeshi, M. (2024) · Bioanalysis · doi:10.1007/978-981-97-6540-9_2
Ultrasound Guided Local Delivery of Bioorthogonal PDL1 Degrader for Enhanced Immunotherapy
Wang, L., Liu, Z., Ji, P., Ma, J., Mou, K., Zhou, T., Liang, Y., Zhang, B., Wei, M., Yang, G., et al. (2024) · Small · doi:10.1002/smll.202405549 · Cited by 1
Targeted anticancer pre-vinylsulfone covalent inhibitors of carbonic anhydrase IXPreprint
Vaškevičius, A., Baronas, D., Leitāns, J., Kvietkauskaitė, A., Rukšėnaitė, A., Manakova, E., Toleikis, Z., Kaupinis, A., Kazāks, A., Gedgaudas, M., et al. (2024) · eLife · doi:10.7554/elife.101401.2 · Cited by 1
Wu, G., Li, X., Liu, S., Mou, J., Zhang, S., Huda, M., Chaiwat, W., & Huang, Y. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5679814
Liu, P., Liu, Y., Cheng, L., Bao, T., Li, J., Wu, J., Han, J., Li, T., & Zhang, D. (2026) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2026.2612805
Wang, S., Wang, L., Hadisurya, M., Nia, S. S., Tao, W. A., Dykhuizen, E. C., & Krusemark, C. J. (2026) · Angewandte Chemie · doi:10.1002/ange.202516630
Chemical probes to interrogate biological systems
Ende, C. W. A., Field, S. D., Majmudar, J. D., & Schenone, M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00055-8
A Hetero-multivalent Covalent Strategy for Enhanced Pulmonary Fibrosis TherapyPreprint
Ge, G., Zhu, G., Deng, Y., Wu, H., Zhang, H., Zhu, G., Zeng, H., Li, N., Wang, L., Fan, Y., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-9244913/v1
Zhao, X., Zhao, Y., Fang, Z., Wei, N., Chen, J., Wang, Q., & Yan, X. Y. (2026) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6c00131
Bottlinger, M., Morici, M., Fajardo-Ruiz, E., Gantner, I., Brameyer, S., Isselstein, M., Berger, M. J., Wilson, D. N., Jung, K., & Sieber, S. A. (2026) · ACS Chemical Biology · doi:10.1021/acschembio.5c01018
Iuga, E., Gone, N., de Godoy, M. O., Veríssimo, G. C., Agostinetto, G. D. J., Urich, L., Krüger, N., Kronenberger, T., Guido, R. V. C., O’Donoghue, A. J., et al. (2026) · ChemMedChem · doi:10.1002/cmdc.202600007
“…cysteine proteases, offers advantages over noncovalent methods, including higher target affinity, the need for lower concentrations due to longer residence time on the target [41, 42], reduced sensitivity to pharmacokinetic factors, and decreased vulnerability to drug resistance [41, 43, 44].”
Ede, R., Peterson, K. E., Begyinah, R. K., Tom, I. P., Ochoada, J., Sneddon, M., Tiu, A. K. Y., Fischer, M., Shelat, A. A., & Pomerantz, W. C. K. (2026) · ChemMedChem · doi:10.1002/cmdc.70301
Chemical Space Exploration of a Database of Covalent Binders in the PDB
Velasco-Saavedra, M. A., Mar-Antonio, E., Colorado-Pablo, L. F., Santos‐Contreras, M. Á., Flores-León, C. D., Carreón-Escalante, M., Sánchez-Maza, S., Ambrosio-Huerta, A., Goode‐Romero, G., Medina‐Franco, J. L., et al. (2026) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6c00846 · Cited by 1
Versatile Sulfonium Tools for Chemoselective Modification of Proteins
ZHAO, Y., Luo, T., & Wu, M. (2026) · Biochemistry · doi:10.1021/acs.biochem.6c00279
Toward targeted covalent inhibition of Cruzipain for the treatment of Chagas disease
Canepa, J. I. E., Ribone, S. R., GRICH, A., Cerutti, J. P., & Quevedo, M. A. (2026) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2026.130744
High‐Throughput Technologies for Targeted Covalent Drug Discovery: Recent Advances and Perspectives
Yu, H., Wang, X., Wang, X., & Yin, Y. (2026) · Chemistry - A European Journal · doi:10.1002/chem.71680
BindingDB Entry 50016732: The Ascension of Targeted Covalent Inhibitors.
BindingDB (2023) · UC San Diego · doi:10.7270/q23f4tpf
BindingDB Entry 50013003: Drugging the undruggable: a computational chemist's view of KRAS
BindingDB (2022) · UC San Diego · doi:10.7270/q2db85kh
BindingDB (2025) · UC San Diego · doi:10.7270/q2vh5th3
BindingDB Entry 50021792: Histidine-Covalent Stapled Alpha-Helical Peptides Targeting hMcl-1.
BindingDB (2025) · UC San Diego · doi:10.7270/q21v5kn0
BindingDB Entry 50015655: Lysine Covalent Antagonists of Melanoma Inhibitors of Apoptosis Protein.
BindingDB (2023) · UC San Diego · doi:10.7270/q2988c0r
BindingDB Entry 50023438: Covalent-Allosteric Inhibitors: Do We Get the Best of Both Worlds?
BindingDB (2026) · UC San Diego · doi:10.7270/q2h136xb
BindingDB Entry 50015871: Advanced approaches of developing targeted covalent drugs.
BindingDB (2023) · UC San Diego · doi:10.7270/q2df6w53
BindingDB (2024) · UC San Diego · doi:10.7270/q2668jc4
BindingDB Entry 50014256: A sulfonyl fluoride derivative inhibits EGFR
BindingDB (2022) · UC San Diego · doi:10.7270/q2sq946r
BindingDB Entry 50015722: Discovery of Cysteine-targeting Covalent Protein Kinase Inhibitors.
BindingDB (2023) · UC San Diego · doi:10.7270/q2hq43wx
BindingDB (2025) · UC San Diego · doi:10.7270/q2db86mc
BindingDB Entry 50009450: Discovery and optimization of covalent Bcl-xL antagonists.
BindingDB (2021) · UC San Diego · doi:10.7270/q2p84gct
BindingDB Entry 50015268: Discovery of Pteridine-7(8
BindingDB (2023) · UC San Diego · doi:10.7270/q2k93cfh
BindingDB (2026) · UC San Diego · doi:10.7270/q2x63swc
BindingDB (2022) · UC San Diego · doi:10.7270/q28s4tqw
BindingDB (2024) · UC San Diego · doi:10.7270/q2zk5n38
BindingDB (2026) · UC San Diego · doi:10.7270/q23201sz
Jiao, X., Wu, G., Li, X., Liu, S., Du, C., Zhang, S., & Huang, Y. (2026) · ChemSusChem · doi:10.1002/cssc.71190
Metadata
- Authors
- Lonsdale, R., & Ward, R. A.
- Affiliations
- AstraZeneca (United Kingdom) (GB)
- Corresponding author
- Ward, Richard A.
- Venue
- Chemical Society Reviews
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2018
- Volume
- 47
- Issue
- 11
- Pages
- 3816-3830
- ISSN
- 0306-0012 (ISSN-L)
- 1460-4744
- OpenAlex
- W2796108867
- Cited by
- 344
- References
- 49
- Citations by year
- 2026: 30 · 2025: 42 · 2024: 46 · 2023: 49 · 2022: 47 · 2021: 45 · 2020: 46 · 2019: 31 · 2018: 8
- FWCI
- 2.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Chemical Society Reviews (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AstraZeneca
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Physical Sciences › Chemistry › Organic Chemistry › Click Chemistry and Applications
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- targeted covalent inhibitors, covalent inhibition, structure-based drug design, reactive functional groups, small molecule inhibitors, inhibitor selectivity, covalent drug discovery
- MeSH terms
- Humans, Drug Design, Molecular Structure, Small Molecule Libraries
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.